EUVIMEDEUVIMED entdecken
Multizentrische Studie

Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Syunsuke Kitamura und 6 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18360 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Anticancer Research, 2026. Verfasst von Tomoki Hori und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nara Prefecture General Medical Center, Nara, Japan. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Hepatocellular, Liver Neoplasms, Proteinuria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabCarcinoma, HepatocellularLiver NeoplasmsProteinuriaSodium-Glucose Transporter 2 InhibitorsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Hepatocellular carcinomabevacizumabproteinuriasodium glucose transporter 2 inhibitors

Substanzen

BevacizumabSodium-Glucose Transporter 2 InhibitorsAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Department of Pharmacy, Nara Prefecture General Medical Center, Nara, Japan.
  • Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
  • Department of Pharmacy, Kobe University Hospital, Kobe, Japan; yamakz@okayama-u.ac.jp.
  • Department of Integrated Clinical and Basic Pharmaceutical Science, Okayama University, Okayama, Japan.
  • Department of Pharmacy, Nara Medical University Hospital, Nara, Japan.
  • Department of Pharmacy, Tenri Hospital, Tenri, Japan.

Zitieren

APA

Hori, T., Yamamoto, K., Aoi, H., Koizumi, Y., Kuromatsu, M., Fukui, A., Okamoto, H., Hirata, A., Shinmori, K., Imanaka, Y., Namba, M., Kitamura, S., Nakanishi, K., Tsushima, H., Yano, I., Moriya, K., Matsui, M., & Ikushima, S. (2026). Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer Research. https://doi.org/10.21873/anticanres.18360

Vancouver

Hori T, Yamamoto K, Aoi H, Koizumi Y, Kuromatsu M, Fukui A, et al. Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer Research. 2026. doi:10.21873/anticanres.18360

BibTeX
@article{Hori2026,
  author = {Hori, Tomoki and Yamamoto, Kazuhiro and Aoi, Hiroshi and Koizumi, Yusuke and Kuromatsu, Makoto and Fukui, Aiko and Okamoto, Hiroyo and Hirata, Atsushi and Shinmori, Kentaro and Imanaka, Yuki and Namba, Miyu and Kitamura, Syunsuke and Nakanishi, Keisuke and Tsushima, Hideo and Yano, Ikuko and Moriya, Kei and Matsui, Masaru and Ikushima, Shigeki},
  title = {Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18360}
}
Kostenlos starten →